Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1874J)

• Drug Name: TRC105 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Angiosarcoma	2B56	Phase 3	[1]
Hemangiosarcoma	2B56.1	Phase 3	[2]
Fallopian tube cancer	2C74	Phase 2	[3]
Gestational trophoblastic neoplasia	2F33-2F76	Phase 2	[2]
Hepatocellular carcinoma	2C12.02	Phase 2	[2]
Macular degeneration	9B78.3	Phase 2	[3]
Ovarian cancer	2C73	Phase 2	[3]
Peritoneal cancer	2C51.Z	Phase 2	[3]
Recurrent glioblastoma	2A00.00	Phase 2	[4]
Renal cell carcinoma	2C90	Phase 2	[2]
Soft tissue sarcoma	2B57	Phase 2	[5]
Breast cancer	2C60-2C65	Phase 1	[2]
Lung cancer	2C25.0	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM1874J

Molecule-Related Drug Atlas

Drug(s) Targeting Endoglin CD105 (ENG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ENV-105	DMC1SRK	Non-small-cell lung cancer	2C25	Phase 1	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Endoglin CD105 (ENG)	TTB30LE	EGLN_HUMAN	Modulator	[6]

References

• [1] ClinicalTrials.gov (NCT02979899) Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26.
• [7] Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918.